Drugs / Atovaquone-proguanil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00379821 | Feb 2007 → Aug 2009 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03278808 Background | Sep 2018 → Dec 2019 | malaria | U.S. Army Medical Research and Development Command | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | atovaquone-proguanil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03278808 ↗ |
| Known as | Malarone | “A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.” NCT03278808 ↗ |